Business Description
Zynerba Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US98986X1090
Compare
Compare
Traded in other countries / regions
ZYNE.USA6ZY.Germany0M40.UK IPO Date
2015-08-05Description
Zynerba Pharmaceuticals Inc is a pharmaceutical company that is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product pipeline consists of Zygel which is a pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 164.99 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 19.2 | |||||
| 3-Year EPS without NRI Growth Rate | 18.2 | |||||
| 3-Year FCF Growth Rate | 30.1 | |||||
| 3-Year Book Growth Rate | -33.3 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.46 | |||||
| 9-Day RSI | 62.43 | |||||
| 14-Day RSI | 70.49 | |||||
| 6-1 Month Momentum % | 176.6 | |||||
| 12-1 Month Momentum % | 39.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.43 | |||||
| Quick Ratio | 3.43 | |||||
| Cash Ratio | 3.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -27.3 | |||||
| Shareholder Yield % | -0.11 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -83.81 | |||||
| ROA % | -68.58 | |||||
| ROIC % | -1279.05 | |||||
| ROC (Joel Greenblatt) % | -5241.35 | |||||
| ROCE % | -86.26 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.48 | |||||
| Price-to-Tangible-Book | 2.48 | |||||
| EV-to-EBIT | -0.96 | |||||
| EV-to-EBITDA | -0.96 | |||||
| EV-to-Forward-EBITDA | -0.72 | |||||
| EV-to-FCF | -1.13 | |||||
| Price-to-Net-Current-Asset-Value | 2.58 | |||||
| Price-to-Net-Cash | 2.98 | |||||
| Earnings Yield (Greenblatt) % | -104.17 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ZYNE
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zynerba Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.8 | ||
| Beta | 0.34 | ||
| Volatility % | 279.56 | ||
| 14-Day RSI | 70.49 | ||
| 14-Day ATR ($) | 0.043211 | ||
| 20-Day SMA ($) | 1.33075 | ||
| 12-1 Month Momentum % | 39.56 | ||
| 52-Week Range ($) | 0.25 - 1.4 | ||
| Shares Outstanding (Mil) | 53.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zynerba Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zynerba Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zynerba Pharmaceuticals Inc Frequently Asked Questions
What is Zynerba Pharmaceuticals Inc(ZYNE)'s stock price today?
The current price of ZYNE is $1.34. The 52 week high of ZYNE is $1.40 and 52 week low is $0.25.
When is next earnings date of Zynerba Pharmaceuticals Inc(ZYNE)?
The next earnings date of Zynerba Pharmaceuticals Inc(ZYNE) is 2023-11-14 Est..
Does Zynerba Pharmaceuticals Inc(ZYNE) pay dividends? If so, how much?
Zynerba Pharmaceuticals Inc(ZYNE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers